stoxline Quote Chart Rank Option Currency Glossary
  
LumiraDx Limited (LMDX)
0.016  0 (0%)    05-13 16:00
Open: 0.0211
High: 0.0282
Volume: 120,553,903
  
Pre. Close: 0.016
Low: 0.0151
Market Cap: 250(M)
Technical analysis
2024-05-17 4:46:56 PM
Short term     
Mid term     
Targets 6-month :  0.02 1-year :  0.03
Resists First :  0.02 Second :  0.02
Pivot price 0
Supports First :  0.01 Second :  0.01
MAs MA(5) :  0 MA(20) :  0
MA(100) :  0 MA(250) :  0
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  0 D(3) :  0
RSI RSI(14): 0
52-week High :  0.02 Low :  0.01
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ LMDX ] has closed Bollinger Bands are 0% narrower than normal.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: - -
Low: - -
Close: - -
Company Description

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Headline News

Sun, 12 May 2024
What Makes LumiraDx Limited (LMDX) a New Buy Stock - Yahoo Movies UK

Thu, 09 May 2024
LumiraDx Limited (LMDX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo New Zealand News

Sat, 13 Jan 2024
LumiraDX Goes Public In SPAC Merger :: Medtech Insight - Medtech Insight

Mon, 08 Jan 2024
Why LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving Premarket - Ainos (NASDAQ:AI - Benzinga

Mon, 08 Jan 2024
Why Is LumiraDx (LMDX) Stock Down 13% Today? - InvestorPlace

Fri, 05 Jan 2024
LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Shares Out 0 (M)
Shares Float 0 (M)
Held by Insiders 0 (%)
Held by Institutions 0 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android